These forwardlooking statements include statements regarding the potentially transformative benefits of SRP9001 our plan to analyze the functional results for all the patients in Study 102 once they have achieved the 48week timepoint the expectation to have biomarker and safety results from Study 103 in the second quarter of 2021 our plan to use the information and insight from Study 102 to refine and complete the protocol for our upcoming trial using commercial process material and our intention to continue to move forward with diligence and urgency to generate the evidence necessary to bring SRP9001 to waiting Duchenne patients around the world